Clinical TrialJul 9, 2026, 07:02 AM
Opus Genetics to Announce OPGx-BEST1 Phase 1/2 Data in Sept 2026
AI Summary
Opus Genetics provided an update on its OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting inherited retinal diseases. The company expects to announce three-month topline data from Cohort 1 in the second week of September 2026 and plans to present this data at the EURETINA Congress in October 2026. Cohort 1 enrollment was completed in May 2026 with five participants, and the trial aims to evaluate the safety and efficacy of OPGx-BEST1.
Key Highlights
- Opus Genetics to announce OPGx-BEST1 Phase 1/2 Cohort 1 topline data in Sept 2026.
- Data will be presented at the EURETINA Congress in Vienna, Oct 1-4, 2026.
- BIRD-1 trial is an adaptive, open-label Phase 1/2 study for OPGx-BEST1.
- Cohort 1 enrollment completed in May 2026 with five participants.
- Primary endpoint for Cohort 1 is safety and tolerability of OPGx-BEST1.
- Trial may expand into a pivotal trial if 100% fluid reduction is observed.
- Company to enter investor relations quiet period from July 15, 2026.
Price Impact
More from IRD